Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-C354 Alone and With Tislelizumab in Advanced Solid Tumors
NCT06422520Phase 1Completed
- Sponsor
- BeOne Medicines
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of BGB-C354 in solid tumor (advanced stage) (4 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 24 months, Maximum Tolerated Dose or Maximum Administered Dose of BGB-C354 at 1 month and 3 more. Started Jul 2024; status: completed.
02
Drugs
BGB-C354
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06422520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422520.